ROCKET PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.98 USD | -0.54% |
|
-3.60% | -26.66% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,233 | 3,322 | 1,407 | 1,481 | 2,702 | 1,989 | - | - |
| Enterprise Value (EV) 1 | 1,233 | 3,066 | 1,018 | 1,125 | 2,295 | 1,826 | 1,930 | 1,742 |
| P/E ratio | -14.4 x | -21.8 x | -8.18 x | -6 x | -10.3 x | -8.27 x | -11.7 x | 157 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 67.3 x | 10.7 x | 4.15 x |
| EV / Revenue | - | - | - | - | - | 61.8 x | 10.4 x | 3.63 x |
| EV / EBITDA | -16.2 x | -23 x | -6.21 x | -5.94 x | -9.01 x | -7.84 x | -15.2 x | 11.8 x |
| EV / FCF | -14 x | -32.2 x | -7.91 x | -6.03 x | -10.9 x | -8.05 x | -9.86 x | -38.2 x |
| FCF Yield | -7.13% | -3.11% | -12.7% | -16.6% | -9.21% | -12.4% | -10.1% | -2.62% |
| Price to Book | - | 6.03 x | 3.1 x | 3.16 x | 5.49 x | 5.55 x | 6.11 x | 3.62 x |
| Nbr of stocks (in thousands) | 54,174 | 60,570 | 64,443 | 75,684 | 90,159 | 90,504 | - | - |
| Reference price 2 | 22.76 | 54.84 | 21.83 | 19.57 | 29.97 | 21.98 | 21.98 | 21.98 |
| Announcement Date | 3/5/20 | 2/25/21 | 2/24/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 29.54 | 185.7 | 479.7 |
| EBITDA 1 | -76.05 | -133.2 | -164 | -189.4 | -254.7 | -233 | -126.7 | 147.6 |
| EBIT 1 | -76.15 | -134.3 | -167.2 | -224.3 | -259.7 | -265.3 | -221.1 | -78.13 |
| Operating Margin | - | - | - | - | - | -897.92% | -119.04% | -16.29% |
| Earnings before Tax (EBT) 1 | -77.27 | -139.7 | -169.1 | -221.9 | -245.6 | -271.2 | -236.6 | -63.35 |
| Net income 1 | -77.27 | -139.7 | -169.1 | -221.9 | -245.6 | -261.5 | -216.8 | -95 |
| Net margin | - | - | - | - | - | -885.31% | -116.74% | -19.8% |
| EPS 2 | -1.580 | -2.520 | -2.670 | -3.260 | -2.920 | -2.659 | -1.878 | 0.1403 |
| Free Cash Flow 1 | -87.93 | -95.25 | -128.8 | -186.5 | -211.4 | -226.8 | -195.6 | -45.58 |
| FCF margin | - | - | - | - | - | -767.57% | -105.35% | -9.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 2/25/21 | 2/24/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | 0.1111 | 4.394 | 28.95 | 33.18 |
| EBITDA 1 | -48.84 | -43.28 | - | -53.18 | -49.73 | -58.34 | -52.14 | -57.32 | -53.89 | -61.88 | -63.69 | -69.97 | -61.09 | -20.19 | - |
| EBIT 1 | -49.65 | -44.33 | -42.56 | -54.21 | -58.49 | -69.08 | -62.19 | -68.76 | -65.43 | -63.28 | -63.94 | -67.09 | -68.08 | -50.32 | -40.3 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | -60,383.03% | -1,549.4% | -173.81% | -121.45% |
| Earnings before Tax (EBT) 1 | -50.12 | -44.25 | -42.98 | -54.4 | -57.76 | -66.72 | -58.34 | -65.7 | -61.9 | -59.66 | -64.28 | -66.3 | -67.5 | -65.23 | -39.9 |
| Net income 1 | -50.12 | -44.25 | -42.98 | -54.4 | -57.76 | -66.72 | -58.34 | -65.7 | -61.9 | -59.66 | -61.05 | -63.84 | -64.6 | -63.55 | -39.9 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | -57,455.91% | -1,470.24% | -219.5% | -120.24% |
| EPS 2 | -0.7900 | -0.6900 | -0.6700 | -0.8300 | -0.8700 | -0.8900 | -0.7300 | -0.8200 | -0.7500 | -0.6400 | -0.6696 | -0.6962 | -0.7050 | -0.6627 | -0.4500 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/24/22 | 5/5/22 | 8/8/22 | 11/3/22 | 2/27/23 | 5/4/23 | 8/9/23 | 11/7/23 | 2/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 256 | 389 | 356 | 407 | 163 | 59.3 | 248 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -87.9 | -95.2 | -129 | -187 | -211 | -227 | -196 | -45.6 |
| ROE (net income / shareholders' equity) | - | -34.5% | -35.3% | -47% | -50% | -62.5% | -45.7% | 9.94% |
| ROA (Net income/ Total Assets) | - | -29% | -31.1% | -42.3% | -43.9% | -57.9% | -62.5% | -32.3% |
| Assets 1 | - | 481.5 | 543.9 | 524.4 | 559.1 | 451.7 | 346.9 | 294.1 |
| Book Value Per Share 2 | - | 9.090 | 7.050 | 6.190 | 5.460 | 3.960 | 3.600 | 6.070 |
| Cash Flow per Share 2 | - | - | -1.920 | -2.610 | -2.320 | -2.540 | -2.030 | - |
| Capex 1 | 23.3 | 20.6 | 7.62 | 8.36 | 16.4 | 10.7 | 10.9 | 10.6 |
| Capex / Sales | - | - | - | - | - | 36.08% | 5.85% | 2.2% |
| Announcement Date | 3/5/20 | 2/25/21 | 2/24/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
21.98
USD
Average target price
50.31
USD
Spread / Average Target
+128.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.66% | 1.99B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RCKT Stock
- Financials Rocket Pharmaceuticals, Inc.
